ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Cabana Target Leading Sector Conservative ETF

Cabana Target Leading Sector Conservative ETF (CLSC)

19,275
0,00
(0,00%)
Fermé 21 Décembre 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
19,275
Prix Achat
14,32
Prix Vente
30,83
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
19,275
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

CLSC Dernières nouvelles

Dr. Gerald Yakatan, Former President and CEO of Avanir Pharmaceuticals, Joins Cobalis Corp. Board of Directors

IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical development company specializing in anti-allergy medications, announced today...

Cobalis Corp. PreHistin(TM) Approval Process to Be Conducted by OTC Division of FDA

FDA's Office of Nonprescription Products Will Now Handle Marketing Approval Process for Anti-Allergy Drug PreHistin(TM) IRVINE, Calif., Jan. 19 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC...

Cobalis Corp. Adds CFO to Management Team

Thomas Stankovich, Former Vice President and Chief Financial Officer of MP Biomedicals, Ribapharm and ICN / Valeant Pharmaceuticals Joins Cobalis Corp. as Chief Financial Officer IRVINE, Calif...

Cobalis Corp. PreHistin(TM) to Be Granted European Union Patent

European Patent Office Allows New Patent for PreHistin(TM) -- 'Cyanocobalamin Treatment in Allergic Disease' IRVINE, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN...

Cobalis Corp. PreHistin(TM) Significantly Reduces Allergy Symptoms in 714 Patient Phase 3 Clinical Trial

Safe, Non-Drowsy PreHistin(TM) Achieves Clinical and Statistical Significance (p= 0.0028) Versus Placebo; Study Demonstrates Dramatic Reduction in Allergy Symptoms IRVINE, Calif., Oct. 27...

Legal Opinion Reinforces Cobalis Patent

IRVINE, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical biotech company specializing in the development of anti-allergy medications...

Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms i

Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms in Humans IRVINE, Calif., July 20 /PRNewswire-FirstCall/ -- Cobalis...

Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange

Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange IRVINE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC...

Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange

Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange IRVINE, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CBSC) (BULLETIN...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000SP
40000000SP
120000000SP
260000000SP
520000000SP
1560000000SP
2600000000SP
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock